Stockholm - Free Realtime Quote SEK
Flerie AB (publ) (FLERIE.ST)
40.50
+0.24
+(0.60%)
As of 9:00:00 AM GMT+2. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
100
100
--
--
--
Cost of Revenue
--
--
4,158
10,287
14,383
Gross Profit
--
--
93,347
-10,287
-14,383
Operating Expense
43,800
37,900
37,800
139,681
100,807
Operating Income
-43,700
-37,800
-37,800
-149,968
-115,190
Net Non Operating Interest Income Expense
-37,100
42,600
11,100
2,893
-133
Pretax Income
-333,500
-227,900
-561,500
-100,333
-103,043
Tax Provision
-4,100
100
-1,900
--
--
Net Income Common Stockholders
-329,500
-228,000
-559,600
-100,333
-103,043
Diluted NI Available to Com Stockholders
-329,500
-228,000
-559,600
-100,333
-103,043
Basic EPS
-4.00
-3.24
-11.34
-19.00
-21.00
Diluted EPS
-4.00
-3.24
-11.34
-19.00
-21.00
Basic Average Shares
74,802.78
70,471.06
49,347.43
5,326.88
4,833.65
Diluted Average Shares
74,802.78
70,471.06
49,347.43
5,326.88
4,833.65
Total Operating Income as Reported
-301,000
-275,000
-571,100
-103,227
-102,910
Rent Expense Supplemental
--
200
100
--
--
Total Expenses
43,800
37,900
37,800
149,968
115,190
Net Income from Continuing & Discontinued Operation
-329,500
-228,000
-559,600
-100,333
-103,043
Normalized Income
-118,130.88
10,200
-28,602.89
-100,333
-103,043
Interest Income
47,800
46,200
30,300
3,013
--
Interest Expense
82,700
1,400
17,200
120
133
Net Interest Income
-37,100
42,600
11,100
2,893
-133
EBIT
-250,800
-226,500
-544,300
-100,213
-102,910
EBITDA
-250,200
-225,900
-543,700
-99,147
-101,658
Reconciled Cost of Revenue
--
--
4,158
10,287
14,383
Reconciled Depreciation
600
600
600
1,066
1,252
Net Income from Continuing Operation Net Minority Interest
-329,500
-228,000
-559,600
-100,333
-103,043
Total Unusual Items Excluding Goodwill
-214,000
-238,200
-532,800
--
--
Total Unusual Items
-214,000
-238,200
-532,800
--
--
Normalized EBITDA
-36,200
12,300
-10,900
-99,147
-101,658
Tax Rate for Calcs
0
--
0
--
--
Tax Effect of Unusual Items
-2,630.88
--
-1,802.89
--
--
12/31/2021 - 6/11/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BT3.BE Lineage Cell Therapeutics Inc
0.4020
+8.06%
GON.DU Geron Corp
1.2080
-1.31%
HTD.MU Corcept Therapeutics Inc
60.20
+5.73%
0M4.DU Mersana Therapeutics Inc
0.3365
-0.47%
RASP Actavia Life Sciences, Inc.
0.0040
0.00%
PI3.DU Gubra AS
47.80
-0.87%
PL3.F TuHURA Biosciences, Inc.
3.5200
-1.68%
50BA.F Bicycle Therapeutics plc
7.30
-3.80%
300759.SZ Pharmaron Beijing Co., Ltd.
23.08
+1.58%
GNRO.PA GeNeuro SA
0.0780
0.00%